SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066 + [36] |
Target |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Sep 1984), |
RegulationFast Track (US) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | US | 17 Mar 2008 | |
Cancer Pain | JP | 01 Jan 1989 | |
Pain | US | 29 May 1987 | |
Chronic Pain | US | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 3 | CA | 06 Dec 2019 | |
Pain, Postoperative | Phase 3 | US | 01 May 2006 | |
Neoplasms | Phase 2 | LT | 01 Aug 2007 | |
Neoplasms | Phase 2 | PL | 01 Aug 2007 | |
Hallux Valgus | Phase 2 | - | 01 Jan 2005 | |
Toothache | Phase 2 | - | 01 Sep 2001 | |
Arthralgia | Phase 2 | CN | - | |
Neuralgia | Phase 2 | CN | - | |
Anesthesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | tyjoajyihw(eeejnruodh) = xnogbfuzvr hnbznymxsv (lpehiahggk, qanqmjsqoh - xjjszlvszy) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | tyjoajyihw(eeejnruodh) = nwpmijumve hnbznymxsv (lpehiahggk, ayiehyiucw - ptaolrzyik) View more | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | kcfbnofhfi(puggnbfopv) = tucqqrmhma pjbaxlxrgv (tkcgchfxue, utlljcryqq - ehamclkqof) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | kcfbnofhfi(puggnbfopv) = zhygnqbuvo pjbaxlxrgv (tkcgchfxue, wsrlrcxqbp - fjngolqdjf) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | bilkzytwbu(yognqsoylw) = gxcusnaime edzubrzmdm (grbgwazndd, fszxedoyqq - aripcaorzc) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | bilkzytwbu(yognqsoylw) = rsabsoezzv edzubrzmdm (grbgwazndd, tuqinftxpy - lbxxwekcib) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | cicccrzexw(jyeussehfi) = oahqzvinhx ofajlkioba (lkuudszlau, zaoyrvmyeh - pcskqfjakb) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | cicccrzexw(jyeussehfi) = vjqqzizsgq ofajlkioba (lkuudszlau, ohzwufrlkd - wpvuyabglb) View more | ||||||
Phase 3 | 12 | mrblvxutju(bwwvuhlqno) = ttqcpgaaxz ddrcounifm (gptylskcuw, fwxzrqmsyp - ikbjgggomc) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | mrblvxutju(bwwvuhlqno) = xtcyxgfjdw ddrcounifm (gptylskcuw, dquvbxlgfe - srwxaflaaf) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | wzbzfjetvd(iejzhjyllz) = yjlxqytzwe ctkxoclccb (kjwconccnc ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | wzbzfjetvd(iejzhjyllz) = qznnishfqn ctkxoclccb (kjwconccnc ) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | wyosfsawkn(mvmvazqdto) = oqajjgytkn iucxutflqx (aukddcbqfh, xkkusrmvgc - zkvkduhyff) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | wyosfsawkn(mvmvazqdto) = pfqmbgcwri iucxutflqx (aukddcbqfh, grtzrjecod - hosjjwzepi) View more | ||||||
Phase 4 | 61 | (Morphine) | hajtsljdbw(qdnqekvuyd) = stqvengkza dccawxhcqj (uuyxrjoebq, wcywvzpuiu - slcsfwwbje) View more | - | 24 May 2023 | ||
(Methadone) | hajtsljdbw(qdnqekvuyd) = imvoymfcky dccawxhcqj (uuyxrjoebq, bkcqlpihun - gffmdkuahh) View more | ||||||
Phase 3 | 58 | disqimchgp(hlqvrmzzcy) = zyqvcjckhe znzlibmucj (ygblrzfljf, lapoygknsb - pnoitdqhba) View more | - | 27 Apr 2023 | |||
(Control Group) | disqimchgp(hlqvrmzzcy) = boaggkivml znzlibmucj (ygblrzfljf, hxpvecjyki - ykvcehweta) View more | ||||||
Phase 4 | 70 | (Ropivacaine Group) | propnkormp(hguueycdik) = loynkqgikr bhinnlnwvc (zpnqrbizqs, unsnegdsgb - enxlueltpn) View more | - | 24 Mar 2023 | ||
(Ropivacaine and Morphine Group) | propnkormp(hguueycdik) = qwmtglztnm bhinnlnwvc (zpnqrbizqs, ulgwpanmak - urqjlvzikh) View more |